BofA analyst Jason Zemansky raised the firm’s price target on BridgeBio (BBIO) to $54 from $50 and keeps a Buy rating on the shares. After speaking to key opinion leaders, the firm has greater conviction in encaleret’s opportunity and more clarity into ‘418’s potential for upside, leading it to raise forecasts, the analyst tells investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma’s Promising Growth Potential Driven by Attruby and Upcoming Pivotal Readouts for Encaleret and BBP-418
- TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
- BridgeBio Pharma Annual Meeting Approves Key Proposals
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- BridgeBio initiated with an Outperform at Wolfe Research